Artykuły w czasopismach na temat „EGFR”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „EGFR”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Chemmalar, S., A. R. Intan Shameha, Che Azurahanim Che Abdullah, Nor Asma Ab Razak, Loqman Mohamad Yusof, Mokrish Ajat, Kim Wei Chan i Md Zuki Abu Bakar Zakaria. "Busting the Breast Cancer with AstraZeneca’s Gefitinib". Advances in Pharmacological and Pharmaceutical Sciences 2023 (4.12.2023): 1–26. http://dx.doi.org/10.1155/2023/8127695.
Pełny tekst źródłaRengifo, Charles E., Rancés Blanco, Damián Blanco, Mercedes Cedeño, Milagros Frómeta i Enrique Rengifo Calzado. "Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy". Journal of Biomarkers 2013 (11.12.2013): 1–9. http://dx.doi.org/10.1155/2013/627845.
Pełny tekst źródłaJezierska, Michalina, Anna Owczarzak i Joanna Stefanowicz. "Dimethylarginines in Children after Anti-Neoplastic Treatment". Medicina 58, nr 1 (11.01.2022): 108. http://dx.doi.org/10.3390/medicina58010108.
Pełny tekst źródłaAl-Shaibani, Eshrak, Taylor Young, Eshetu Atenafu, Verna Cheung, Safwan Alsibai, Vikas Gupta, Dawn C. Maze, Marta Beata Davidson, Aniket Banker i Hassan Sibai. "Impact of Kidney Dysfunction on Overall Survival in Myeloproliferative Neoplasms: A Single-Center Retrospective Study". Blood 142, Supplement 1 (28.11.2023): 6439. http://dx.doi.org/10.1182/blood-2023-189318.
Pełny tekst źródłaMaennling, Amaia Eleonora, Mehmet Kemal Tur, Marcus Niebert, Torsten Klockenbring, Felix Zeppernick, Stefan Gattenlöhner, Ivo Meinhold-Heerlein i Ahmad Fawzi Hussain. "Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials". Cancers 11, nr 12 (20.11.2019): 1826. http://dx.doi.org/10.3390/cancers11121826.
Pełny tekst źródłaHuang, Hsien-Neng, Pin-Feng Hung, Yai-Ping Chen i Chia-Huei Lee. "Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer". International Journal of Molecular Sciences 25, nr 3 (23.01.2024): 1374. http://dx.doi.org/10.3390/ijms25031374.
Pełny tekst źródłaNicholson, Christopher J., Samuel J. Roth, Arudhir Singh, Caitlin Brown, Simon P. Fricker, Jon Hu i Samantha Dale Strasse. "Abstract C052: Circumventing EGFR inhibitor resistance in NSCLC using transomics". Molecular Cancer Therapeutics 22, nr 12_Supplement (1.12.2023): C052. http://dx.doi.org/10.1158/1535-7163.targ-23-c052.
Pełny tekst źródłaKumar, Sachin, Jeff Vassallo, Kalpana Nattamai, Jose A. Cancelas i Hartmut Geiger. "EGFR Signaling in Osteoblasts Regulates Circadian Rhythm of HSPC in Circulation". Blood 126, nr 23 (3.12.2015): 665. http://dx.doi.org/10.1182/blood.v126.23.665.665.
Pełny tekst źródłaZhou, Caicun, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng Chih Lin, Margarita Majem i in. "Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 9020. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.9020.
Pełny tekst źródłaLee, Eugine, Padraich Flahardy, Cameron Vergato, Stephen Siecinski, Justin Chen, Charles O’Donnell, Graeme Hodgson, Defne Yarar i Thomas McCauley. "Abstract 1726: Targeted epigenomic control of MYC as a strategy to treat EGFR inhibitor-resistant NSCLC". Cancer Research 84, nr 6_Supplement (22.03.2024): 1726. http://dx.doi.org/10.1158/1538-7445.am2024-1726.
Pełny tekst źródłaGecht, Judith, Ioannis Tsoukakis, Kim Kricheldorf, Frank Stegelmann, Martine Klausmann, Martin Griesshammer, Holger Schulz i in. "Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry". Cancers 13, nr 16 (13.08.2021): 4086. http://dx.doi.org/10.3390/cancers13164086.
Pełny tekst źródłaHoffman, P., i C. Carlin. "Adenovirus E3 protein causes constitutively internalized epidermal growth factor receptors to accumulate in a prelysosomal compartment, resulting in enhanced degradation". Molecular and Cellular Biology 14, nr 6 (czerwiec 1994): 3695–706. http://dx.doi.org/10.1128/mcb.14.6.3695-3706.1994.
Pełny tekst źródłaHoffman, P., i C. Carlin. "Adenovirus E3 protein causes constitutively internalized epidermal growth factor receptors to accumulate in a prelysosomal compartment, resulting in enhanced degradation." Molecular and Cellular Biology 14, nr 6 (czerwiec 1994): 3695–706. http://dx.doi.org/10.1128/mcb.14.6.3695.
Pełny tekst źródłaSimmons, Daniel, Maral DerSarkissian, Rahul Shenolikar, Min-Jung Wang, Angela Lax, Aruna Muthukumar, François Laliberté i Mei Sheng Duh. "Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): e19345-e19345. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19345.
Pełny tekst źródłaSimmons, Daniel, Maral DerSarkissian, Rahul Shenolikar, Min-Jung Wang, Angela Lax, Aruna Muthukumar, François Laliberté i Mei Sheng Duh. "Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting." Journal of Clinical Oncology 38, nr 29_suppl (10.10.2020): 281. http://dx.doi.org/10.1200/jco.2020.38.29_suppl.281.
Pełny tekst źródłaMulherin, Brian Patrick, Jia Zeng, Anupama Vasudevan, Erin Alwon, Mike Gart, Simon Blanc i Stephen G. Divers. "Assessing quality of care in early stage resected stage non-small cell lung cancer (NSCLC): An evaluation of epidermal growth factor receptor (EGFR) testing and adjuvant (adj) therapy (tx)." Journal of Clinical Oncology 42, nr 16_suppl (1.06.2024): 8072. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8072.
Pełny tekst źródłavan de Stadt, Eveline Annette, Maqsood Yaqub, Robert C. Schuit, Imke H. Bartelink, Anke F. Leeuwerik, Lothar A. Schwarte, Adrianus J. de Langen, Harry Hendrikse i Idris Bahce. "Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients". Diagnostics 12, nr 4 (1.04.2022): 883. http://dx.doi.org/10.3390/diagnostics12040883.
Pełny tekst źródłaPardo Aranda, Nuria, Jordi Remon, Alex Martinez Marti, Ana Maria Martinez de Castro, Susana Cedres Perez, Alejandro Navarro, Eulalia Scheenaard i in. "Outcome of EGFR mutant patirnts included in a clinical trial after progression on EGFR TKI." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): e20555-e20555. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20555.
Pełny tekst źródłaHartman, Zachary, Werner J. Geldenhuys i Yehenew M. Agazie. "A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2)". Journal of Biological Chemistry 295, nr 11 (4.02.2020): 3563–75. http://dx.doi.org/10.1074/jbc.ra119.011422.
Pełny tekst źródłaSharabi, Omri, Tomer Ventura, Rivka Manor, Eliahu D. Aflalo i Amir Sagi. "Epidermal Growth Factor Receptor in the Prawn Macrobrachium rosenbergii: Function and Putative Signaling Cascade". Endocrinology 154, nr 9 (1.09.2013): 3188–96. http://dx.doi.org/10.1210/en.2013-1259.
Pełny tekst źródłaKassel, Karen M., Nancy A. Schulte i Myron L. Toews. "Modulation of epidermal growth factor receptor binding to human airway smooth muscle cells by glucocorticoids and β2-adrenergic receptor agonists". American Journal of Physiology-Lung Cellular and Molecular Physiology 296, nr 4 (kwiecień 2009): L693—L699. http://dx.doi.org/10.1152/ajplung.90446.2008.
Pełny tekst źródłaSorkin, A. "Internalization of the epidermal growth factor receptor: role in signalling". Biochemical Society Transactions 29, nr 4 (1.08.2001): 480–84. http://dx.doi.org/10.1042/bst0290480.
Pełny tekst źródłaSantoni-Rugiu, Melchior, Urbanska, Jakobsen, Stricker, Grauslund i Sørensen. "Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance". Cancers 11, nr 7 (1.07.2019): 923. http://dx.doi.org/10.3390/cancers11070923.
Pełny tekst źródłaChouaid, Christos, Laura Luciani, Katell Le Lay i Gerard De Pouvourville. "Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-mutated population with advanced non-small-cell lung cancer." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): e20548-e20548. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e20548.
Pełny tekst źródłaShum, Elaine, Yasir Elamin, Karen L. Reckamp, Zofia Piotrowska, Julia Rotow, Daniel S. Tan, Koichi Goto i in. "Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study". Cancer Research 82, nr 12_Supplement (15.06.2022): CT184. http://dx.doi.org/10.1158/1538-7445.am2022-ct184.
Pełny tekst źródłaYu, Xiaochun, Kailash D. Sharma, Tsuyoshi Takahashi, Ryo Iwamoto i Eisuke Mekada. "Ligand-independent Dimer Formation of Epidermal Growth Factor Receptor (EGFR) Is a Step Separable from Ligand-induced EGFR Signaling". Molecular Biology of the Cell 13, nr 7 (lipiec 2002): 2547–57. http://dx.doi.org/10.1091/mbc.01-08-0411.
Pełny tekst źródłaAbrahams, Beynon, Anthonie Gerber i Donavon Charles Hiss. "Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro". International Journal of Molecular Sciences 25, nr 5 (6.03.2024): 3066. http://dx.doi.org/10.3390/ijms25053066.
Pełny tekst źródłaAhn, Myung-Ju, Silvia Park, Jong-Mu Sun, Jin Seok Ahn, Keunchil Park, Emma J. Langley, Phillip Sangwook Kim, Sharat Singh i Steve Lockton. "Roles of cMET/ErbB3 activation and overexpression in the development of resistance to EGFR inhibitors in NSCLC patients." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): 11113. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.11113.
Pełny tekst źródłaRamalingam, Suresh S., James C. H. Yang, Chee Khoon Lee, Takayasu Kurata, Dong-Wan Kim, Thomas John, Naoyuki Nogami i in. "Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer". Journal of Clinical Oncology 36, nr 9 (20.03.2018): 841–49. http://dx.doi.org/10.1200/jco.2017.74.7576.
Pełny tekst źródłaTavera, Luz, Stefanie Schalm, John Campbell, Jian Guo, Clare Medendorp, Maxine Chen, Faris Albayya i in. "Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC". Cancer Research 82, nr 12_Supplement (15.06.2022): 3328. http://dx.doi.org/10.1158/1538-7445.am2022-3328.
Pełny tekst źródłaGuardiola, Salvador, Mireia Díaz-Lobo, Jesús Seco, Jesús García, Laura Nevola i Ernest Giralt. "Peptides Targeting EGF Block the EGF-EGFR Interaction". ChemBioChem 17, nr 8 (25.01.2016): 702–11. http://dx.doi.org/10.1002/cbic.201500525.
Pełny tekst źródłaPal, Arpita S., Alejandra Agredo, Nadia A. Lanman, Jihye Son, Ikjot Singh Sohal, Manvir Bains, Chennan Li, Jenna Clingerman, Kayla Gates i Andrea L. Kasinski. "Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET". Cancer Research 82, nr 8 (11.04.2022): 1534–47. http://dx.doi.org/10.1158/0008-5472.can-20-0821.
Pełny tekst źródłaNakagawa, Kazuhiko, Edward B. Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Chao-Hua Chiu, Keunchil Park i in. "RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 9000. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.9000.
Pełny tekst źródłaShu, Catherine A., Koichi Goto, Byoung Chul Cho, Frank Griesinger, James Chih-Hsin Yang, Enriqueta Felip, John Xie i in. "CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): TPS9132. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps9132.
Pełny tekst źródłaChung, Tsai-Hua, Jong-Kai Hsiao, Ming Yao, Szu-Chun Hsu, Hon-Man Liu i Dong-Ming Huang. "Ferucarbotran, a carboxydextran-coated superparamagnetic iron oxide nanoparticle, induces endosomal recycling, contributing to cellular and exosomal EGFR overexpression for cancer therapy". RSC Advances 5, nr 109 (2015): 89932–39. http://dx.doi.org/10.1039/c5ra18810e.
Pełny tekst źródłaThomas, C. Y., M. Jameson i A. Beckler. "Interaction of EGFR and IGF-1R signals to modulate the anti-proliferative and biochemical responses of head and neck squamous cancer (HNSCC) cells to EGFR inhibitors". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 6045. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.6045.
Pełny tekst źródłaHarvey, R. Donald, Val R. Adams, Tyler Beardslee i Patrick Medina. "Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings". Journal of Oncology Pharmacy Practice 26, nr 6 (20.06.2020): 1461–74. http://dx.doi.org/10.1177/1078155220931926.
Pełny tekst źródłaKim, Ji Min, Jun Ho Ji, Young Saing Kim, Suee Lee, Sung Yong Oh, Seok Jae Huh, Choon Hee Son i in. "rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects". Cancers 12, nr 11 (25.10.2020): 3120. http://dx.doi.org/10.3390/cancers12113120.
Pełny tekst źródłaOhmori, Tohru, Toshimitsu Yamaoka, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryou Manabe i Hironori Sagara. "Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury". International Journal of Molecular Sciences 22, nr 2 (14.01.2021): 792. http://dx.doi.org/10.3390/ijms22020792.
Pełny tekst źródłaJazieh, Abdul Rahman, Huseyin Cem Onal, Daniel Shao-Weng Tan, Ross A. Soo, Kumar Prabhash, Amit Kumar, Reto Huggenberger i Byoung Chul Cho. "Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study". Therapeutic Advances in Medical Oncology 14 (styczeń 2022): 175883592211227. http://dx.doi.org/10.1177/17588359221122720.
Pełny tekst źródłaUrbanska, Edyta M., Morten Grauslund, Peter R. Koffeldt, Sarah L. B. Truelsen, Johan O. Löfgren, Junia C. Costa, Linea C. Melchior, Jens B. Sørensen i Eric Santoni-Rugiu. "Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC". International Journal of Molecular Sciences 24, nr 17 (23.08.2023): 13077. http://dx.doi.org/10.3390/ijms241713077.
Pełny tekst źródłaAddeo, Alfredo, Maximilian Hochmair, Urska Janzic, Elizabeth Dudnik, Andriani Charpidou, Adam Płużański, Tudor Ciuleanu i in. "Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)". Therapeutic Advances in Medical Oncology 13 (styczeń 2021): 175883592110598. http://dx.doi.org/10.1177/17588359211059874.
Pełny tekst źródłaAgulnik, Jason S., Goulnar Kasymjanova, Carmela Pepe, Manjusha Hurry, Ryan N. Walton, Lama Sakr, Victor Cohen i David Small. "Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec". Current Oncology 28, nr 6 (7.12.2021): 5179–91. http://dx.doi.org/10.3390/curroncol28060434.
Pełny tekst źródłaZubair, Tanzida, i Debasish Bandyopadhyay. "Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities". International Journal of Molecular Sciences 24, nr 3 (31.01.2023): 2651. http://dx.doi.org/10.3390/ijms24032651.
Pełny tekst źródłaNicholson, Christopher J., Arudhir Singh, Caitlin Westberg Brown, Simon P. Fricker, Jon Hu i Samantha Dale Strasser. "Abstract LB063: An integrated transomics approach reveals significant differences between EGFR inhibitors with the potential to identify novel targets to overcome EGFR resistance". Cancer Research 83, nr 8_Supplement (14.04.2023): LB063. http://dx.doi.org/10.1158/1538-7445.am2023-lb063.
Pełny tekst źródłaSacchi, Elizabeth, You Li, Vincent A. Miller, Melissa D. Curtis i Siraj Mahamed Ali. "Real-world racial disparities in EGFR testing and third-generation EGFR TKI use among U.S. patients with stage IV NSCLC." Journal of Clinical Oncology 40, nr 28_suppl (1.10.2022): 124. http://dx.doi.org/10.1200/jco.2022.40.28_suppl.124.
Pełny tekst źródłaWada, I., W. H. Lai, B. I. Posner i J. J. Bergeron. "Association of the tyrosine phosphorylated epidermal growth factor receptor with a 55-kD tyrosine phosphorylated protein at the cell surface and in endosomes." Journal of Cell Biology 116, nr 2 (15.01.1992): 321–30. http://dx.doi.org/10.1083/jcb.116.2.321.
Pełny tekst źródłaKelly, Karen, Nasser K. Altorki, Wilfried E. E. Eberhardt, Mary E. R. O'Brien, David R. Spigel, Lucio Crinò, Chun-Ming Tsai i in. "Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial". Journal of Clinical Oncology 33, nr 34 (1.12.2015): 4007–14. http://dx.doi.org/10.1200/jco.2015.61.8918.
Pełny tekst źródłaMiettinen, Päivi, Päivi Ormio, Elina Hakonen, Meenal Banerjee i Timo Otonkoski. "EGF receptor in pancreatic β-cell mass regulation". Biochemical Society Transactions 36, nr 3 (21.05.2008): 280–85. http://dx.doi.org/10.1042/bst0360280.
Pełny tekst źródłaYamazaki, Tetsuo, Kristien Zaal, Dale Hailey, John Presley, Jennifer Lippincott-Schwartz i Lawrence E. Samelson. "Role of Grb2 in EGF-stimulated EGFR internalization". Journal of Cell Science 115, nr 9 (1.05.2002): 1791–802. http://dx.doi.org/10.1242/jcs.115.9.1791.
Pełny tekst źródła